US Patent 11607451 Self-buffering antibody formulations
Patent 11607451 was granted and assigned to Amgen on March, 2023 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11607451 Self-buffering antibody formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.